The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus.
Scancell Holdings CEO discusses new research programme into coronavirus vaccine
Quick facts: Scancell Holdings PLC
Price: 5.35 GBX
Market Cap: £24.9 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE